A Phase 2/3 interventional study of Unfractionated heparin in Covid19, sponsored by Australian National University. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Australian National University · Phase 2/3, Interventional, and Treatment
This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies. Individual studies will be conducted in multiple countries, including Australia, the UK, the USA, Ireland, Argentina, Brazil and Egypt.
Adult patients admitted to the hospital with confirmed SARS-CoV-2 infection, who do not require immediate mechanical ventilation, will be randomised to inhaled nebulised heparin or standard care for up to 21 days or until the patient has no respiratory symptoms. All studies will collect a minimum core dataset. The primary outcome for the meta-trial is the proportion of patients who receive invasive mechanical ventilation censored at day 28. Individual studies may have specific outcome measures in addition to the core set.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 485 is above the median of 100 across 4,098 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Australian National University is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Inhaled nebulised unfractionated heparin in addition to standard care Dose 25,000 IU every 6 hours for up to 21 days
Drug: Unfractionated heparin
Standard care
Inhaled nebulised 6 hourly
Intubation rate
Proportion of patients requiring invasive mechanical ventilation
Time frame: Day 28
WHO ordinal scale COVID19
Number of patients showing 1 or 2 point worsening on the ordinal scale
Time frame: Day 7
Oxygenation
Daily ratio of partial pressure of oxygen to FiO2 (PaO2/FiO2)
Time frame: Day 7
Plan to share: Undecided — This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian National University